An Oxfordshire-based company that offers needle-free vaccinations has been highlighted by Lord Davies, Minister for Trade, Investment and Small Business, as an example of the power of British life sciences to generate export trade.
Glide Pharma has developed a pen-like device, Glide SDI, that saves children from undergoing painful injections.
With the support of UK Trade & Investment (UKTI), Glide Pharma has just returned from successful trade missions to India and Japan.
The Glide SDI device uses a spring to deliver drugs just under the skin, offering a child-friendly means to carry out vaccinations and inject life-saving drugs such as insulin.
Lord Davis said: “Anyone who has ever had to take a child for an injection will appreciate the benefits of this invention. Glide Pharma is a trailblazer in that it is taking this device to the world. Firms such as this are vital for Britain’s economic future.”
Based in Abingdon, Glide Pharma partners with pharmaceutical companies to apply its proprietary needle-free injection technology.
In the last year, the UK again proved to be the leading country in Europe for attracting R&D investment. Of this, 25% was investment into life sciences.
Speaking at the Harwell Science and Innovation Campus, Lord Davies noted that UKTI had helped to bring £500 million of R&D investment to the UK over the last two and a half years. “In a world where populations are both growing and ageing, life sciences will play an increasingly important role,” he said. “Despite the global recession, life sciences exports rose by 19% per cent last year.
“The dedication and ingenuity of our life sciences firms is not only winning sales overseas but also attracting investors to the UK.”
Glide SDI device